NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Sionna Therapeutics SION

Sionna Therapeutics listed on Nasdaq on 7 Feb 2025 and is not in the S&P 500. It is worth $134 million. Its board has 12 directors, 9 of them independent. 4 other officers are on file. At 30 Jun 2026, Ra Capital Management was its largest institutional holder, with 21.9% of the company.

CEO
Michael Cloonan
Chair
Paul J. Clancy
Listed
7 Feb 2025 on Nasdaq
Headquarters
Waltham, MA
Market cap
$134M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Sionna Therapeutics' market cap since February 2025

Weekly, up to 13 Nov 2026

Apr 2025JulOctJan 2026AprJulOct$150M

Board and leadership

Board and officers

1 person here also holds roles at other S&P 500 companies.

Board from the proxy filed 27 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (12)
Paul J. ClancyChairIndependent 路 since 2022 路 Audit, Nominating and Corporate Governance (chair)Visiting Senior Lecturer of Finance at Cornell University's Graduate School of Management and Executive Fellow at Harvard Business SchoolAlso at IncyteChair2022YesAudit, Nominating and Corporate Governance (chair)64
Michael CloonanPresident & CEONot independent 路 since 2021President & CEO2021No55
Bruce BoothDirectorIndependent 路 since 2020 路 CompensationGeneral Partner, Atlas VentureOther boards: Kymera TherapeuticsDirector2020YesCompensation52
Harold Edward FlemingDirectorIndependent 路 since 2024 路 AuditExecutive Vice President of Commercialization, Enavate Sciences GP, LLCOther boards: Upstream Bio and CRISPR Therapeutics AGDirector2024YesAudit63
Lucian IancoviciDirectorIndependent 路 since 2019 路 CompensationManaging Director, TPG Global, LLCOther boards: RallybioDirector2019YesCompensation44
Peter KolchinskyDirectorDirector
Joshua ResnickDirectorIndependent 路 since 2019Partner, RA Capital Management, L.P.Other boards: PepGen Inc., Aerovate Therapeutics and Vor Biopharma Inc.Director2019Yes51
Marcella K. RuddyDirectorIndependent 路 since 2025 路 Nominating and Corporate GovernanceChief Medical Officer, Tectonic Therapeutic, Inc.Other boards: Upstream BioDirector2025YesNominating and Corporate Governance63
Rajeev M. ShahDirectorDirector
Laurie StelzerDirectorIndependent 路 since 2024 路 Audit (chair), CompensationFormer Chief Financial Officer, Kailera Therapeutics, Inc.Other boards: PMV Pharmaceuticals, Spyre Therapeutics and MBX BiosciencesDirector2024YesAudit (chair), Compensation58
Peter A. ThompsonDirectorIndependent 路 since 2022 路 Nominating and Corporate GovernanceMember, OrbiMed Advisors LLCOther boards: ARS Pharmaceuticals Inc., Corvus Pharmaceuticals and Edgewise TherapeuticsDirector2022YesNominating and Corporate Governance66
Joanne L. VineyDirectorIndependent 路 since 2025 路 Compensation (chair)Chief Executive Officer, Seismic Therapeutic, Inc.Director2025YesCompensation (chair)60
Officers (4)
Elena RidloffCFO and CBOLast filed 18 Sep 2026CFO and CBO
Caroline Stark BeerChief Business OfficerLast filed 6 Jan 2026Chief Business Officer
Jennifer FitzpatrickCLO and Head of Program MgmtLast filed 18 Sep 2026CLO and Head of Program Mgmt
Charlotte McKeeCMO and Head of R&DLast filed 18 Sep 2026CMO and Head of R&D

Owners and trading

Largest institutional holders

Each fund group's share of Sionna Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

  • Ra Capital Management21.9%
  • Tpg GP A14.4%
  • Viking Global Investors7.1%
  • Atlas Venture Life Science Advisors6.6%
  • Orbimed Advisors5.7%

These five hold 55.7% of Sionna Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $81.8 million of stock in 27 sales and made no open-market purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
17 Sep 2026SalePeter KolchinskyDirectorDirectorSale3,448,811$22M
7 Jul 2026SalePeter A. ThompsonDirectorDirectorSale85,918$3.9M
6 Jul 2026SaleJennifer FitzpatrickCLO and Head of Program MgmtCLO and Head of Program MgmtSale10,250$447K
30 Jun 2026SalePeter A. ThompsonDirectorDirectorSale115,844$5.3M
27 May 2026SalePeter A. ThompsonDirectorDirectorSale101$4K
11 May 2026SalePeter A. ThompsonDirectorDirectorSale184,639$8.5M
8 May 2026SalePeter A. ThompsonDirectorDirectorSale59,767$2.7M
7 May 2026SalePeter A. ThompsonDirectorDirectorSale48,546$2.2M
18 Apr 2026SalePeter A. ThompsonDirectorDirectorSale2,948$131K
17 Apr 2026SalePeter A. ThompsonDirectorDirectorSale52,397$2.3M

Showing 10 of 27 trades

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 3 appointments of directors and officers and 14 large insider sales in the last two years.

Left the company or board 1Appointed 3WARN layoff notices 0Large insider sales 14Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Sionna Therapeutics' insider sales.

Events, newest first

Showing 8 of 18 events

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.